<code id='68062A6B74'></code><style id='68062A6B74'></style>
    • <acronym id='68062A6B74'></acronym>
      <center id='68062A6B74'><center id='68062A6B74'><tfoot id='68062A6B74'></tfoot></center><abbr id='68062A6B74'><dir id='68062A6B74'><tfoot id='68062A6B74'></tfoot><noframes id='68062A6B74'>

    • <optgroup id='68062A6B74'><strike id='68062A6B74'><sup id='68062A6B74'></sup></strike><code id='68062A6B74'></code></optgroup>
        1. <b id='68062A6B74'><label id='68062A6B74'><select id='68062A6B74'><dt id='68062A6B74'><span id='68062A6B74'></span></dt></select></label></b><u id='68062A6B74'></u>
          <i id='68062A6B74'><strike id='68062A6B74'><tt id='68062A6B74'><pre id='68062A6B74'></pre></tt></strike></i>

          explore

          explore

          author:entertainment    Page View:8
          dose of methadone
          A dose of methadone Kevin D. Liles/AP

          The federal government is reforming methadone care for the first time in over two decades. But how far do the changes actually go?

          To many methadone clinics, the Biden administration’s recent refresh of the rules governing opioid treatment programs represents an unprecedented opportunity to offer care that is more compassionate and responsive to patients’ needs. To many patient advocates, however, it simply nibbles around the edges. 

          advertisement

          The reality is likely somewhere in between: It will depend, in large part, on whether state-level regulators embrace the changes, and whether individual clinics actually implement them. In reform-oriented states, and at patient-centered clinics, the new rules could make a world of difference for people seeking addiction treatment. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Flagship, Pfizer team up in deal worth up to $7 billion
          Flagship, Pfizer team up in deal worth up to $7 billion

          PaulBiondiFlagshipPharmagiantPfizeristurningtoventurefirmFlagshipfornewdrugdevelopment,signingadealw

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

          CraigF.Walker/TheBostonGlobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togeto